{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T13:31:10Z","timestamp":1789565470685,"version":"build-2803163510"},"update-to":[{"DOI":"10.1002\/14651858.cd008535","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2011,11,9]],"date-time":"2011-11-09T00:00:00Z","timestamp":1320796800000}}],"reference-count":37,"publisher":"Wiley","issue":"11","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd008535.pub2","type":"journal-article","created":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T14:19:44Z","timestamp":1320157184000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Anti-hypertensive drugs as disease-modifying agents for Parkinson's disease: evidence from observational studies and clinical trials"],"prefix":"10.1002","volume":"2011","author":[{"given":"Karen","family":"Rees","sequence":"first","affiliation":[{"name":"Warwick Medical School, University of Warwick; Division of Health Sciences; Coventry UK CV4 7AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Stowe","sequence":"additional","affiliation":[{"name":"University of Birmingham; Birmingham Clinical Trials Unit; Edgbaston Birmingham UK B15 2TT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smitaa","family":"Patel","sequence":"additional","affiliation":[{"name":"University of Birmingham; Birmingham Clinical Trials Unit; Edgbaston Birmingham UK B15 2TT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Ives","sequence":"additional","affiliation":[{"name":"University of Birmingham; Birmingham Clinical Trials Unit; Edgbaston Birmingham UK B15 2TT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kieran","family":"Breen","sequence":"additional","affiliation":[{"name":"Parkinson's Disease Society; Research and Development Directorate; 215 Vauxhall Bridge Road London UK SW1V 1EJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoav","family":"Ben-Shlomo","sequence":"additional","affiliation":[{"name":"Canynge Hall; Dept of Social Medicine; Whiteladies Road Bristol UK BS8 2PR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl E","family":"Clarke","sequence":"additional","affiliation":[{"name":"College of Medicine and Dental Sciences; School of Clinical and Experimental Medicine; University of Birmingham Edgbaston Birmingham West Midlands UK B18 7QH"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,11,9]]},"reference":[{"issue":"16 Pt 2","key":"10.1002\/14651858.CD008535.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1212\/01.wnl.0000303818.38960.44","article-title":"Use of antihypertensives and the risk of Parkinson disease","volume":"70","author":"Becker","year":"2008","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD008535.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1159\/000235641","article-title":"Antihypertensive Agents and Risk of Parkinson's Disease, Essential Tremor and Dementia: A Population-Based Prospective Study (NEDICES)","volume":"33","author":"Louis","year":"2009","journal-title":"Neuroepidemiology"},{"issue":"2","key":"10.1002\/14651858.CD008535.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1159\/000054770","article-title":"Risk factors for Parkinson's disease: the leisure world cohort study","volume":"20","author":"Paganini-Hill","year":"2001","journal-title":"Neuroepidemiology"},{"issue":"1","key":"10.1002\/14651858.CD008535.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1445-5994.2000.tb01054.x","article-title":"The angiotensin converting enzyme (ACE) inhibitor, perindopril, modifies the clinical features of Parkinson's disease","volume":"30","author":"Reardon","year":"2000","journal-title":"Australian and New Zealand Journal of Medicine"},{"key":"10.1002\/14651858.CD008535.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/ana.21937","article-title":"L-Type Calcium Channel Blockers and Parkinson Disease in Denmark","volume":"67","author":"Ritz","year":"2010","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1002\/14651858.CD008535.pub2-BIB0006|cit6","first-page":"2","article-title":"[Treatment of sialorrhea in Parkinson's disease patients with clonidine. Double-blind, comparative study with placebo]","volume":"18","author":"Serrano-Duenas","year":"2003","journal-title":"Neurologia"},{"issue":"12","key":"10.1002\/14651858.CD008535.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1002\/mds.23191","article-title":"Calcium Channel Blocker Use and Risk of Parkinson's Disease","volume":"25","author":"Simon","year":"2010","journal-title":"Movement Disorders"},{"key":"10.1002\/14651858.CD008535.pub2-BIB0008|cit8","unstructured":"Safety, tolerability and efficacy assessment of Dynacirc CR in Parkinson Disease (STEADY-PD) ClinicalTrials.gov NCT00909545"},{"key":"10.1002\/14651858.CD008535.pub2-BIB0009|cit9","unstructured":"Simuni T Biglan K Oakes D Gardiner N Deeley C Surmeier DJ Movement Disorders 2009 1874 1875"},{"key":"10.1002\/14651858.CD008535.pub2-BIB0010|cit10","unstructured":"Simuni T Biglan K Oakes D Gardiner N Deeley C Surmeier DJ Parkinsonism and Related Disorders 2009"},{"issue":"3","key":"10.1002\/14651858.CD008535.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.parkreldis.2006.08.011","article-title":"Calcium channel blockers and beta-blockers in relation to Parkinson's disease","volume":"13","author":"Ton","year":"2007","journal-title":"Parkinsonism & Related Disorders"},{"key":"10.1002\/14651858.CD008535.pub2-BIB0012|cit12","first-page":"314","article-title":"Incompatability of flunarizine in Parkinson's disease: results from a double blind trial","volume-title":"New trends in clinical neuropharmacology","author":"Hefner","year":"1988"},{"issue":"3","key":"10.1002\/14651858.CD008535.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0306-4522(99)00037-8","article-title":"The alpha2 agonist, clonidine, improves spatial working performance in Parkinson's disease","volume":"92","author":"Riekkinen","year":"1999","journal-title":"Neuroscience"},{"issue":"6","key":"10.1002\/14651858.CD008535.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"845","DOI":"10.2165\/00003495-199957060-00001","article-title":"Can calcium antagonists provide a neuroprotective effect in Parkinson's disease?","volume":"57","author":"Rodnitzky","year":"1999","journal-title":"Drugs"},{"key":"10.1002\/14651858.CD008535.pub2-BIB0015|cit15","first-page":"162","article-title":"Safety and tolerability of isradipine, a dihydropyridine calcium channel blocker, in patients with early Parkinson's disease","volume":"23 Suppl 1","author":"Simuni","year":"2008","journal-title":"Movement Disorders"},{"issue":"16","key":"10.1002\/14651858.CD008535.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1002\/mds.23308","article-title":"Tolerability of Isradipine in Early Parkinson's Disease: A Pilot Dose Escalation Study","volume":"25","author":"Simuni","year":"2010","journal-title":"Movement Disorders"},{"issue":"2","key":"10.1002\/14651858.CD008535.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1001\/archneur.1975.00490440084016","article-title":"Clonidine in Parkinson disease","volume":"32","author":"Tarsy","year":"1975","journal-title":"Archives of Neurology"},{"issue":"6","key":"10.1002\/14651858.CD008535.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1212\/01.wnl.0000344171.22760.24","article-title":"Use of antihypertensives and the risk of Parkinson disease","volume":"72","author":"Ascherio","year":"2009","journal-title":"Neurology"},{"issue":"3","key":"10.1002\/14651858.CD008535.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.molmed.2009.01.001","article-title":"Calcium signalling and neurodegenerative diseases","volume":"15","author":"Bezprozvanny","year":"2009","journal-title":"Trends in Molecular Medicine"},{"key":"10.1002\/14651858.CD008535.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/0006-8993(94)90534-7","article-title":"Locus coeruleus lesions potentiate neurotoxic effects of MPTP in dopaminergic neurons of the substantia nigra","volume":"668","author":"Bing","year":"1994","journal-title":"Brain Research"},{"issue":"5","key":"10.1002\/14651858.CD008535.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1002\/mds.22461","article-title":"A case of Parkinson's disease worsened by captopril: an unexpected adverse effect","volume":"24","author":"Chang","year":"2009","journal-title":"Movement Disorders"},{"key":"10.1002\/14651858.CD008535.pub2-BIB0022|cit22","doi-asserted-by":"crossref","DOI":"10.1002\/9780470712184.ch13","article-title":"Chapter 13: Including non-randomised studies","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Reeves","year":"2008"},{"issue":"1","key":"10.1002\/14651858.CD008535.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1177\/106002809502900113","article-title":"Extrapyramidal symptoms associated with calcium-channel blockers","volume":"29","author":"Daniel","year":"1995","journal-title":"Annals of Pharmacotherapy"},{"issue":"1","key":"10.1002\/14651858.CD008535.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"28","DOI":"10.2174\/187152708783885192","article-title":"Will it ever become possible to prevent dopaminergic neuronal degeneration?","volume":"7","author":"Giovanni","year":"2008","journal-title":"CNS and Neurological Disorders - Drug Targets"},{"issue":"3","key":"10.1002\/14651858.CD008535.pub2-BIB0025|cit25","first-page":"187","article-title":"[Increase in Parkinson symptoms caused by calcium antagonists]. [German] Zunahme der Parkinson-Symptomatik unter Kalzium-Antagonisten","volume":"60","author":"Hefner","year":"1989","journal-title":"Der Nervenarzt"},{"key":"10.1002\/14651858.CD008535.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1001\/archneur.62.3.378","article-title":"Nonlinear progression of Parkinson Disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F18 activity","volume":"62","author":"Hilker","year":"2005","journal-title":"Archives of Neurology"},{"issue":"6","key":"10.1002\/14651858.CD008535.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/jnr.20598","article-title":"Angiotensin-converting enzyme inhibition reduces oxidative stress and protects dopaminergic neurons in a 6-hydroxydopamine rat model of Parkinsonism","volume":"81","author":"Lopez-Real","year":"2005","journal-title":"Journal of Neuroscience Research"},{"key":"10.1002\/14651858.CD008535.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.2165\/0023210-200822120-00006","article-title":"Pharmacotherapy of essential tremor: an overview of existing and upcoming agents","volume":"22","author":"Lyons","year":"2008","journal-title":"CNS Drugs"},{"issue":"2","key":"10.1002\/14651858.CD008535.pub2-BIB0029|cit29","first-page":"153","article-title":"Cardiovascular autonomic dysfunction in parkinsonian patients","volume":"5","author":"Mathias","year":"1998","journal-title":"Clinical Neuroscience"},{"issue":"5","key":"10.1002\/14651858.CD008535.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/00002826-199510000-00004","article-title":"Effects of calcium antagonists on the dopamine system","volume":"18","author":"Mena","year":"1995","journal-title":"Clinical Neuropharmacology"},{"issue":"1","key":"10.1002\/14651858.CD008535.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.neuropharm.2006.03.004","article-title":"Reduction of dopaminergic degeneration and oxidative stress by inhibition of angiotensin converting enzyme in a MPTP model of parkinsonism","volume":"51","author":"Munoz","year":"2006","journal-title":"Neuropharmacology"},{"key":"10.1002\/14651858.CD008535.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/j.1532-5415.2004.52178_7.x","article-title":"Angiotensin-converting enzyme inhibitors and incidence of Alzheimers disease in Japan","volume":"52","author":"Ohrui","year":"2004","journal-title":"Journal of the American Geriatrics Society"},{"issue":"8","key":"10.1002\/14651858.CD008535.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1586\/14737175.6.8.1173","article-title":"Blood pressure disorders during Parkinson's disease: epidemiology, pathophysiology and management","volume":"6","author":"Pathak","year":"2006","journal-title":"Expert Review of Neurotherapeutics"},{"issue":"7","key":"10.1002\/14651858.CD008535.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1002\/mds.21945","article-title":"A case of Parkinsonism worsened by losarten: a probable new adverse effect","volume":"23","author":"Sarma","year":"2008","journal-title":"Movement Disorders"},{"issue":"1","key":"10.1002\/14651858.CD008535.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.tips.2008.10.005","article-title":"Neurobiology and treatment of Parkinson's disease","volume":"30","author":"Schapira","year":"2009","journal-title":"Trends in Pharmacological Sciences"},{"issue":"10","key":"10.1002\/14651858.CD008535.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S1474-4422(07)70246-6","article-title":"Calcium, ageing, and neuronal vulnerability in Parkinson's disease","volume":"6","author":"Surmeier","year":"2007","journal-title":"Lancet Neurology"},{"key":"10.1002\/14651858.CD008535.pub2-BIB0037|cit37","unstructured":"Wells GA Shea B O'Connell D Peterson J Welch V Losos M Tugwell P The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses Available from: www.ohri.ca\/programs\/clinical_epidemiology\/oxford.htm 2008"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD008535.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T17:31:31Z","timestamp":1753464691000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD008535.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Movement Disorders Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2011,11,9]]},"references-count":37,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2011,11]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd008535.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,11,9]]}}}